Enhanced cytotoxic effect of low doses of metformin combined with ionizing radiation on hepatoma cells via ATP deprivation and inhibition of DNA repair

Oncology Reports

Volumn 28, Issue 4, 2012, Pages 1406-1412

  Liu, Jifang ^a   Hou, Min ^a   Yuan, Taize ^a   Yi, Gao ^a   Zhang, Shuxu ^a   Shao, Xunfan ^a   Chen, Jinhui ^b   Jia, Xiaoting ^a   He, Zhimin ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b Qingyuan Polytechnic   (China)

Author keywords

Adenosine triphosphate; DNA repair; Hepatocellular carcinoma; Ionizing radiation; Metformin

Indexed keywords

ADENOSINE TRIPHOSPHATE; GAMMA HISTONE H2AX; HISTONE H2AX; LACTATE DEHYDROGENASE; METFORMIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER CELL DESTRUCTION; CANCER RADIOTHERAPY; CELL SURVIVAL; CELL VIABILITY; CHEMORADIOTHERAPY; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENERGY METABOLISM; ENERGY YIELD; ENZYME ACTIVITY; G2 PHASE CELL CYCLE CHECKPOINT; GLYCOLYSIS; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADENOSINE TRIPHOSPHATE; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY METABOLISM; HISTONES; HUMANS; HYDRO-LYASES; LIVER NEOPLASMS; METFORMIN; RADIATION, IONIZING;

EID: 84866453607     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1932     Document Type: Article

References (42)

1. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007.
2. El-Serag HB, Davila JA, Petersen NJ and McGlynn KA: The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139: 817-823, 2003.
3. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS and Ten Haken RK: Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53: 810-821, 2002.
4. Mornex F, Girard N, Beziat C, Kubas A, Khodri M, Trepo C and Merle P: Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies - mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 66: 1152-1158, 2006.
5. Girard N and Mornex F: External radiotherapy for hepatocellular carcinoma. Cancer Radiother 15: 49-53, 2011.
6. Liang SX, Zhu XD, Lu HJ, et al: Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma. Cancer 103: 2181-2188, 2005.
7. Diamanti-Kandarakis E, Economou F, Palimeri S and Christakou C: Metformin in polycystic ovary syndrome. Ann NY Acad Sci 1205: 192-198, 2010.
8. Bianchi C, Penno G, Romero F, Del Prato S and Miccoli R: Treating the metabolic syndrome. Expert Rev Cardiovasc Ther 5: 491-506, 2007.
9. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305, 2005.
10. Kourelis TV and Siegel RD: Metformin and cancer: new applications for an old drug. Med Oncol 29: 1314-1327, 2012.
11. Tennant DA, Durán RV and Gottlieb E: Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10: 267-277, 2010.
12. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF and Bost F: Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 9: 1092-1099, 2010.
13. Zakikhani M, Dowling RJ, Sonenberg N and Pollak MN: The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) 1: 369-375, 2008.
14. Dowling RJ, Zakikhani M, Fantus IG, Pollak M and Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-10812, 2007.
15. Hardie DG: Adenosine monophosphate-activated protein kinase: a central regulator of metabolism with roles in diabetes, cancer, and viral infection. Cold Spring Harb Symp Quant Biol 76: 155-164, 2011.
16. Buzzai M, Jones RG, Amaravadi RK, et al: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752, 2007.
17. Hou M, Venier N, Sugar L, et al: Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet. Biochem Biophys Res Commun 397: 537-542, 2010.
18. Hassan MM, Curley SA, Li D, et al: Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116: 1938-1946, 2010.
19. Lalau JD and Race JM: Lactic acidosis in metformin therapy. Drugs 1: 55-60, 1999.
20. Vanderlinde RE: Measurement of total lactate dehydrogenase activity. Ann Clin Lab Sci 15: 13-31, 1985.
21. van Dyk E and Pretorius PJ: DNA damage and repair in mammalian cells exposed to p-hydroxyphenylpyruvic acid. Biochem Biophys Res Commun 338: 815-819, 2005.
22. Gu YX, Fan SS, Xiong Y, et al: Cloning and functional characterization of TCRP1, a novel gene mediating resistance to cisplatin in an oral squamous cell carcinoma cell line. FEBS Lett 585: 881-887, 2011.
23. Ortega AD, Sánchez-Aragó M, Giner-Sánchez D, Sánchez-Cenizo L, Willers I and Cuezva JM: Glucose avidity of carcinomas. Cancer Lett 276: 125-135, 2009.
24. Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW and Weitz J: Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 253: 453-469, 2011.
25. Sanli T, Rashid A, Liu C, et al: Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys 78: 221-229, 2010.
26. Kinner A, Wu W, Staudt C and Iliakis G: Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36: 5678-5694, 2008.
27. Judit PB, Susan HM and Peggy LO: Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines. Cancer Res 64: 7144-7149, 2004.
28. Klokov D, MacPhail SM, Banáth JP, Byrne JP and Olive PL: Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays. Radiother Oncol 80: 223-229, 2006.
29. Raju U, Nakata E, Yang P, Newman RA, Ang KK and Milas L: In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys 54: 886-894, 2002.
30. Huang G, Wang H and Yang LX: Enhancement of radiation-induced DNA damage and inhibition of its repair by a novel camptothecin analog. Anticancer Res 30: 937-944, 2010.
31. Petermann E, Ziegler M and Oei SL: ATP-dependent selection between single nucleotide and long patch base excision repair. DNA Repair 2: 1101-1114, 2003.
32. Lammens K, Bemeleit DJ, Mockel C, et al: The Mre11:Rad50 structure shows an ATP-dependent molecular clamp in DNA double-strand break repair. Cell 145: 54-66, 2011.
33. Lyamzaev KG, Izyumov DS and Avetisyan AV: Inhibition of mitochondrial bioenergetics: the effects on structure of mitochondria in the cell and on apoptosis. Acta Biochim Pol 51: 553-562, 2004.
34. Halicka HD, Zhao H, Li JW, Traganos1 F, Zhang SF, Lee M and Darzynkiewicz1 Z: Genome protective effect of metformin as revealed by reduced level of constitutive DNA damage signaling. Aging 3: 1-11, 2011.
35. Hirsch HA, Iliopoulos D, Tsichlis PN and Struhl K: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69: 7507-7511, 2009.
36. Kisfalvi K, Eibl G, Sinnett-Smith J and Rozengurt E: Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69: 6539-6545, 2009.
37. Ben Sahra I, Laurent K, Loubat A, et al: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27: 3576-3586, 2008.
38. Algire C, Zakikhani M, Blouin MJ, Shuai JH and Pollak M: Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 15: 833-839, 2008.
39. Rattan R, Giri S, Hartmann LC and Shridhar V: Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 15: 166-178, 2011.
40. Scheen AJ: Clinical pharmacokinetics of metformin. Clin Pharmacokinet 30: 359-371, 1996.
41. Isoda K, Young JL, Zirlik A, et al: Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 26: 611-617, 2006.
42. Graham GG, Punt J, Arora M, et al: Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50: 81-98, 2011.